Recommended Treatment Approach for ADHD with Stimulants

First-Line Treatment Options

The American Academy of Child and Adolescent Psychiatry recommends methylphenidate as the first-line stimulant medication for ADHD due to its rapid onset of treatment effects and large effect sizes 1, 3
Methylphenidate is available in multiple formulations, including short-acting and long-acting/extended-release, which provide 3-5 hours and throughout the day of symptom control, respectively 3, 4
Lisdexamfetamine should be considered as the next option if methylphenidate is ineffective at adequate dosage and duration 1, 2

The American Academy of Pediatrics recommends monitoring height and weight, especially in children, as well as blood pressure and pulse, when using stimulants for ADHD treatment 1, 6

Atomoxetine takes 6-12 weeks for full effect and requires monitoring for suicidality due to an FDA black box warning 1, 6
Alpha-2 adrenergic agonists, such as extended-release guanfacine or clonidine, are alternative non-stimulant options that take 2-4 weeks for full effect and require monitoring of blood pressure and pulse 1, 6

The initial assessment should confirm ADHD diagnosis using DSM criteria and assess for comorbidities that may influence treatment choice 1, 2, 7
The treatment algorithm recommends starting with methylphenidate, preferably extended-release formulation, and titrating gradually based on response and tolerability 1, 3, 5

Rebound effects may occur with short-acting stimulants, and extended-release formulations should be considered to mitigate this risk 1, 3
Growth effects, such as changes in height and weight, should be monitored in children, and cardiovascular concerns, such as increased blood pressure and heart rate, should be considered when using stimulants 4, 6